Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service cochlear implants cases in Florida: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 23% on average (17 state-years, 2020–2024): small markets swing, so treat it as rough.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 10 | 282 | 49% |
| 2020 | 8 | 246 | 52% |
| 2021 | 11 | 275 | 54% |
| 2022 | 10 | 250 | 56% |
| 2023 | 12 | 312 | 58% |
| 2024 | 9 | 349 | 60% |
| 2025 from claims | – | 255 207–300 | 61% |
| 2026 forecast | – | 264 207–332 | 61% |
| 2027 forecast | – | 273 202–361 | 61% |
| 2028 forecast | – | 281 199–388 | 62% |
| 2029 forecast | – | 290 197–416 | 62% |
| 2030 forecast | – | 299 196–444 | 63% |
Cochlear implantation, children and adults. Professional codes (what the surgeon bills): CPT 69930.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Florida; 7 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 70% hospital outpatient, 30% surgery center. The share outside the hospital has moved +8 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| Forecast, Medicare FFS | Hospital outpatient | Surgery center |
|---|---|---|
| 2026 · ~260 | ~180 | ~81 |
| 2027 · ~270 | ~190 | ~84 |
| 2028 · ~280 | ~190 | ~87 |
The forecast’s cases at the projected mix.
If the trend since 2022 holds, slowing as it goes, by 2028: surgery center about 31% (30% in 2025), hospital outpatient about 69% (70% in 2025). More of these cases each year are decided in surgery centers, where the surgeons often own the center and weigh price and turnaround.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Texas | 9 | 288+1.6%/yr | +1.6%/yr | 0.1 | 13% | 330 in 2030+2.2%/yr |
| Tennessee | 7 | 205+8.7%/yr | +8.7%/yr | 0.3 | 28% | 290 in 2030+6.2%/yr |
| North Carolina | 5 | 192+9.9%/yr | +9.9%/yr | 0.2 | 21% | 300 in 2030+7.5%/yr |
| South Carolina | 6 | 142+4.7%/yr | +4.7%/yr | 0.2 | 17% | 310 in 2030+14%/yr |
| Georgia | 4 | 121+12%/yr | +12%/yr | 0.1 | 0% | 230 in 2030+11%/yr |
| Maryland | 4 | 116+2.8%/yr | +2.8%/yr | 0.1 | 0% | 100 in 2030−2.1%/yr |
| Virginia | 3 | 115+6.7%/yr | +6.7%/yr | 0.1 | 0% | 150 in 2030+4.4%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Sinus surgery & balloon dilation | 144 | 14,5270%/yr | 0%/yr | 6.61.4× | 92% | 19,700 in 2030+5.2%/yr |
| Ear tubes & middle ear surgery | 6 | 650−5.8%/yr | −5.8%/yr | 0.30.9× | 70% | 680 in 2030+0.7%/yr |
| Sleep apnea & airway implants | 17 | 501+55%/yr | +55%/yr | 0.20.9× | 6% | 600 in 2030+3.1%/yr |
Cochlear implants in every state, and its device makers · Every procedure market in Florida · Every state · Compare with Texas
Cochlear leads with 57% of company spending on these surgeons in 2025, +33 pts on 2024.
In 2025, 7 companies reported engagement with Florida’s surgeons worth $69K in consulting, speaking, meals and travel tied to these products, about $7,686 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 15 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.